It seemed that TP53 mutation carriers tended to develop HER2-positive breast cancer (33.3%, 2/6) more often than did BRCA mutation carriers (3.4%, 3/88) and non-carriers (7.1% (23/326). Here, ERBB2 is linked to breast carcinoma.